

Resource Summary Report

Generated by [dkNET](#) on Aug 16, 2026

Phospho-Akt (Ser473) (736E11) Rabbit mAb

RRID:AB_331170

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3787, RRID:AB_331170

Antibody Information

URL: http://antibodyregistry.org/AB_331170

Proper Citation: Cell Signaling Technology Cat# 3787, RRID:AB_331170

Target Antigen: Phospho-Akt (Ser473) (736E11) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: IHC-P, IHC-F. Consolidation on 9/2016: AB_331171. Info: Used By NYUIHC-466.

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: Phospho-Akt (Ser473) (736E11) Rabbit mAb

Description: This monoclonal targets Phospho-Akt (Ser473) (736E11) Rabbit mAb

Target Organism: h, m, mouse, human

Clone ID: Clone 736E11

Antibody ID: AB_331170

Vendor: Cell Signaling Technology

Catalog Number: 3787

Alternative Catalog Numbers: 3787L, 3787S

Record Creation Time: 20250819T224341+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Phospho-Akt (Ser473) (736E11) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 32 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Fieblinger T, et al. (2026) Repurposing drugs for treating the neurobehavioral manifestations of PTEN hamartoma tumor syndrome. iScience, 29(4), 115428.

Mayr L, et al. (2025) Effective targeting of PDGFRA-altered high-grade glioma with avapritinib. Cancer cell, 43(4), 740.

Almazan J, et al. (2025) Combined inhibition of focal adhesion kinase and RAF/MEK elicits synergistic inhibition of melanoma growth and reduces metastases. Cell reports. Medicine, 6(2), 101943.

Lv Y, et al. (2025) IFITM2 Modulates Endocytosis Maintaining Neural Stem Cells in Developing Neocortex. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(17), e2501593.

Theardy MS, et al. (2025) Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. Cell reports. Medicine, 6(8), 102253.

Sin SH, et al. (2024) The complete Kaposi sarcoma-associated herpesvirus genome induces early-onset, metastatic angiosarcoma in transgenic mice. Cell host & microbe, 32(5), 755.

Ku AT, et al. (2023) Short-term PI3K Inhibition Prevents Breast Cancer in Preclinical Models. Cancer prevention research (Philadelphia, Pa.), 16(2), 65.

Mancarella C, et al. (2023) Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K/Akt pathway in neighboring cells. *Cancer gene therapy*, 30(9), 1285.

Gao X, et al. (2023) Deletion of the tyrosine phosphatase Shp2 in cervical cancer cells promotes reprogramming of glutamine metabolism. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 37(4), e22880.

Verma R, et al. (2023) Olig1/2-Expressing Intermediate Lineage Progenitors Are Predisposed to PTEN/p53-Loss-Induced Gliomagenesis and Harbor Specific Therapeutic Vulnerabilities. *Cancer research*, 83(6), 890.

Lin TY, et al. (2023) Epinephrine inhibits PI3K? via the Hippo kinases. *Cell reports*, 42(12), 113535.

Wilmott JS, et al. (2023) Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(3), 521.

Song WM, et al. (2023) Pseudo-temporal dynamics of chemoresistant triple negative breast cancer cells reveal EGFR/HER2 inhibition as synthetic lethal during mid-neoadjuvant chemotherapy. *iScience*, 26(2), 106064.

Steiner I, et al. (2023) Autocrine activation of MAPK signaling mediates intrinsic tolerance to androgen deprivation in LY6D prostate cancer cells. *Cell reports*, 42(4), 112377.

Lee JH, et al. (2022) Alzheimer's disease protease-containing plasma extracellular vesicles transfer to the hippocampus via the choroid plexus. *EBioMedicine*, 77, 103903.

Lin CC, et al. (2022) Receptor tyrosine kinases regulate signal transduction through a liquid-liquid phase separated state. *Molecular cell*, 82(6), 1089.

Zhao X, et al. (2022) Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function. *Cancer research*, 82(11), 2185.

Chaves FM, et al. (2022) Effects of the Isolated and Combined Ablation of Growth Hormone and IGF-1 Receptors in Somatostatin Neurons. *Endocrinology*, 163(5).

Gusmao DO, et al. (2022) Increased GH Secretion and Body Growth in Mice Carrying Ablation of IGF-1 Receptor in GH-releasing Hormone Cells. *Endocrinology*, 163(11).

Carrabotta M, et al. (2022) Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma. *Cancer research*, 82(4), 708.